Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Corvus Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Corvus Pharmaceuticals, Inc.’s stock price such as:

• Corvus Pharmaceuticals, Inc.’s current stock price and volume
• Why Corvus Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for CRVS from analysts
• CRVS’s stock price momentum as measured by its relative strength

About Corvus Pharmaceuticals, Inc. (CRVS)

Before we jump into Corvus Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Want to learn more about Corvus Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Corvus Pharmaceuticals, Inc..

Corvus Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of March 13, 2026, 4:00 PM, CST, Corvus Pharmaceuticals, Inc.’s stock price was $15.320.

Corvus Pharmaceuticals, Inc. is down 4.31% from its previous closing price of $16.010.

During the last market session, Corvus Pharmaceuticals, Inc.’s stock traded between $14.590 and $16.440. Currently, there are approximately 83.00 million shares outstanding for Corvus Pharmaceuticals, Inc..

Corvus Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Corvus Pharmaceuticals, Inc. Stock Price History

Corvus Pharmaceuticals, Inc.’s (CRVS) price is currently down 16.1% so far this month.

During the month of March, Corvus Pharmaceuticals, Inc.’s stock price has reached a high of $18.260 and a low of $14.590.

Over the last year, Corvus Pharmaceuticals, Inc. has hit prices as high as $26.950 and as low as $2.540. Year to date, Corvus Pharmaceuticals, Inc.’s stock is up 98.96%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Corvus Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 13, 2026, there were 0 analysts who downgraded Corvus Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Corvus Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Corvus Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Corvus Pharmaceuticals, Inc. (CRVS) by visiting AAII Stock Evaluator.

Relative Price Strength of Corvus Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 13, 2026, Corvus Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 45.91%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Corvus Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Corvus Pharmaceuticals, Inc. Stock Price: Bottom Line

As of March 13, 2026, Corvus Pharmaceuticals, Inc.’s stock price is $15.320, which is down 4.31% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Corvus Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.